< Zurück zu den aktuellen Neuigkeiten & Events

Brexit

Brexit and Trade Mark Protection in the UK

Dezember 2019

On the 12th December 2019 the Conservatives won the UK General Election. Their campaign was very much on a promise to “get Brexit done” and this provides more certainty on the outcome and timetable of Brexit.

It is now widely expected that the UK Parliament will pass the necessary EU Withdrawal Act so the UK will formally leave the European Union on 31st January 2020.

However, this does not mean that the UK will be leaving the EUIPO system at that time. The UK will continue to be part of the EU trade mark and design registration systems during a transitional period whilst a full trade deal between the UK and EU is negotiated. This transitional period will maintain this status quo until at least January 2021, but depending on how long these complicated negotiations take, could last considerably longer.

HGF will keep you promptly updated on developments and will notify you as and when UK trade mark protection is impacted.

However, for the foreseeable future, it remains “business as usual” with the UK remaining part of the EUIPO and EU trade mark/design registration systems.

When the UK eventually does leave the EUIPO system, HGF will ensure all your trade mark rights are maintained and protected in the EU and the UK by taking all necessary actions on your behalf.

With offices in 6 European countries, HGF is ideally placed to assist clients through Brexit process and continue to handle all EU and UK trade mark design and other intellectual property matters as we do now. We will continue to be your trusted advisors and representatives at both the EUIPO and the UKIPO.

If you have any queries at all, please contact your usual HGF Trade Mark Attorney, or David Potter, Head of the HGF Trade Mark team.

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen